Drug General Information
Drug ID
D0NQ0V
Former ID
DNCL003699
Drug Name
BT-061
Drug Type
Antibody
Indication Psoriasis; Asthma [ICD9: 696; ICD10:L40, J45] Phase 2 [522956], [533077]
Company
Biotest
Target and Pathway
Target(s) T-cell surface glycoprotein CD4 Target Info [533138]
KEGG Pathway Cell adhesion molecules (CAMs)
Antigen processing and presentation
Hematopoietic cell lineage
T cell receptor signaling pathway
Primary immunodeficiency
NetPath Pathway Leptin Signaling Pathway
Pathway Interaction Database TCR signaling in na&#xef
IL12-mediated signaling events
CXCR4-mediated signaling events
C-MYB transcription factor network
IL23-mediated signaling events
Arf1 pathway
Notch-mediated HES/HEY network
IL12 signaling mediated by STAT4
Reactome Binding and entry of HIV virion
Phosphorylation of CD3 and TCR zeta chains
Translocation of ZAP-70 to Immunological synapse
Generation of second messenger molecules
PD-1 signaling
WikiPathways TCR Signaling Pathway
Cytokines and Inflammatory Response
Host Interactions of HIV factors
Defensins
HIV Life Cycle
TCR signaling
Costimulation by the CD28 family
References
Ref 522956ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
Ref 533077A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405.
Ref 533138Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.